www.成人自慰,国产超碰人人模人人爽人人喊,免费午夜爽爽爽www视频十八禁,人妻丰满熟妇av无码区hd

產(chǎn)品展示 / products 您的位置:網(wǎng)站首頁(yè) > 產(chǎn)品展示 > 細(xì)胞庫(kù) > 細(xì)胞系 > 人乳腺癌細(xì)胞MCF-7
相關(guān)文章

Related articles

人乳腺癌細(xì)胞MCF-7

人乳腺癌細(xì)胞MCF-7

簡(jiǎn)要描述:青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺(tái),在標(biāo)準(zhǔn)化細(xì)胞庫(kù)建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營(yíng)原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測(cè)等科研產(chǎn)品與服務(wù)。我們秉承對(duì)用戶負(fù)責(zé)的態(tài)度,以對(duì)科研的高度嚴(yán)謹(jǐn),以嚴(yán)格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)!

更新時(shí)間:2021-05-26

廠商性質(zhì):生產(chǎn)廠家

瀏覽次數(shù):366

詳情介紹
品牌其他品牌貨號(hào)BFN607200603
規(guī)格T25培養(yǎng)瓶x1 1.5ml凍存管x2供貨周期現(xiàn)貨
主要用途僅供科研應(yīng)用領(lǐng)域醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細(xì)胞名稱

人乳腺癌細(xì)MCF-7

img1

貨物編碼

BFN607200603

產(chǎn)品規(guī)格

T25培養(yǎng)x1

1.5ml凍存x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級(jí)

1

用途限制

僅供科研用途               1類

 

培養(yǎng)體系

DMEM高糖培養(yǎng)+20%FBS+1%三抗

培養(yǎng)溫度

37

二氧化碳濃度

5%

簡(jiǎn)介

人乳腺癌細(xì)MCF-7細(xì)胞是從一69歲的白人女性乳腺癌患者的胸腔積液中分離建立的。該細(xì)胞保留了多個(gè)分化乳腺上皮的特性,包括:能通過胞質(zhì)雌激素受體加工雌二醇并能形成隆突結(jié)構(gòu)domes);該細(xì)胞表達(dá)WNT7B癌基因;TNF-α可以抑MCF-7細(xì)胞的生長(zhǎng);抗雌激素處理能調(diào)節(jié)細(xì)胞胰島素樣生長(zhǎng)因子結(jié)合蛋白IGFBP)的分泌。人乳腺癌細(xì)MCF-7細(xì)胞引種ATCC HIB-22

注釋

Group: Space-flown cell line (cellonaut).

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 2.

Part of: JFCR39 cancer cell line panel.

Part of: JFCR45 cancer cell line panel.

Part of: GrayJW Breast Cancer Cell Line Panel.

Part of: ICBP43 breast cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Registration: Chiron Master Culture Collection; CMCC 10377 (CMCC #10377).

Doubling time: 1.8 days (PubMed=9671407); 80 hours (PubMed=25984343); 31.2 hours (PubMed=22628656); 25.4 hours (NCI-DTP); ~50 hours, with a range of 30-72 hours (DSMZ); ~38 hours (PBCF); 56.47 hours 

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: Glycoproteome analysis by proteomics.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: H3K27me3 ChIP-seq epigenome analysis.

Omics: H3K36me3 ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: H3K9me3 ChIP-seq epigenome analysis.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: miRNA expression profiling.

Omics: Myristoylated proteins analysis by proteomics.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Virome analysis using proteomics.

Anecdotal: This is the first hormone-responsive breast cancer cell line to have been established.

Anecdotal: Helen Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun (Sister Catherine Frances) at the Immaculate Heart of Mary Convent in Monroe, Michigan.

Anecdotal: Have been flown in space on Foton-12 to study cytoskeleton architecture in microgravity (PubMed=11292682; PubMed=15002416).

Misspelling: MFC-7; Occasionally.

STR信息

AmelogeninX;CSF1PO10;D13S31711;D16S53911,12D18S5114;D19S4331314;D21S1130;D2S133821,23D3S135816;D5S8181112;D7S8208,9;D8S117910,14FGA23,24,25;TH016TPOX9,12;vWA14,15

參考文獻(xiàn)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470

Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.

Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.

J. Proteome Res. 16:1391-1400(2017)

 

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Andersen C.L., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

 

PubMed=28889351; DOI=10.1007/s10549-017-4496-x

Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Breast Cancer Res. Treat. 167:289-301(2018)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

驗(yàn)收細(xì)胞注意事項(xiàng) 

1、收到人乳腺癌細(xì)MCF-7細(xì)胞,請(qǐng)查看瓶子是否有破裂,培養(yǎng)基是否漏出,是否渾濁,如有請(qǐng)盡快聯(lián)系。 

2、收到人乳腺癌細(xì)MCF-7細(xì) ,如包裝完好,請(qǐng)?jiān)陲@微鏡下觀察細(xì)胞。,由于運(yùn)輸過程中的問題,細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來,顯微鏡下觀察會(huì)出現(xiàn)細(xì)胞懸浮的情況,出現(xiàn)此狀態(tài)時(shí),請(qǐng)不要打開細(xì)胞培養(yǎng)瓶,應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜 3-5 小時(shí)左右,讓細(xì)胞先穩(wěn)定下,再于顯微鏡下觀察,此時(shí)多數(shù)細(xì)胞會(huì)重新貼附于瓶壁。如細(xì)胞仍不能貼壁,請(qǐng)用臺(tái)盼藍(lán)染色法鑒定細(xì)胞活力,如臺(tái)盼藍(lán)染色證實(shí)細(xì)胞活力正常請(qǐng)按懸浮細(xì)胞的方法處理。 

3、收到人乳腺癌細(xì)MCF-7細(xì)胞后,請(qǐng)鏡下觀察細(xì)胞,用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多,請(qǐng)離心收集細(xì)胞,接種到一個(gè)新的培養(yǎng)瓶中。棄掉原液,使用新鮮配制的培養(yǎng)基,使用進(jìn)口胎牛血清。剛接到細(xì)胞,若細(xì)胞不多時(shí) 血清濃度可以加 15%去培養(yǎng)。若細(xì)胞迏 80% ,血清濃度還是 10。 

4、收到人乳腺癌細(xì)MCF-7細(xì)胞時(shí)如無異常情 ,請(qǐng)?jiān)陲@微鏡下觀察細(xì)胞密度,如為貼壁細(xì)胞,未超80%匯合度時(shí),將培養(yǎng)瓶中培養(yǎng)基吸出,留 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng):超 80%匯合度時(shí),請(qǐng)按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞,吸出培養(yǎng)液,1000 轉(zhuǎn)/分鐘離 3 分鐘,吸出上清,管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶。 

5、將培養(yǎng)瓶置 37培養(yǎng)箱中培養(yǎng),蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時(shí)之需。 

624 小時(shí)后,細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁,即可傳代。(貼壁細(xì)胞)將培養(yǎng)瓶里的培養(yǎng)基倒去, 3-5ml(以能覆蓋細(xì)胞生長(zhǎng)面為準(zhǔn)PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時(shí)間以具體細(xì)胞為準(zhǔn),一 1-3 分鐘,不超 5 分鐘??梢苑?/span>37培養(yǎng)箱消化。輕輕晃動(dòng)瓶壁,見細(xì)胞脫落下來,加 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞,使之*脫落,然后將溶液吸入離心管內(nèi)離心,1000rpm/5min。棄上清,視細(xì)胞數(shù)量決定分瓶數(shù),一般一傳二,如細(xì)胞量多可一傳三,有些細(xì)胞不易傳得過稀,有些生長(zhǎng)較快的細(xì)胞則可以多傳幾瓶,以具體細(xì)胞和經(jīng)驗(yàn)為準(zhǔn)。(懸浮細(xì)胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可。 

7、貼壁細(xì) ,懸浮細(xì)胞。嚴(yán)格無菌操作。換液時(shí),換新的細(xì)胞培養(yǎng)瓶和換新鮮的培養(yǎng)液,37,5%CO2 培養(yǎng)。

 

特別提醒 原瓶中培養(yǎng)基不宜繼續(xù)使用,請(qǐng)更換新鮮培養(yǎng)基培養(yǎng)。



留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

聯(lián)